Cookies

Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Diagnostics Microbiology and immunology

Making Moves on Monkeypox

Credit: National Institute of Allergy and Infectious Diseases (CC BY 2.0).

As we gain footholds in the fight against COVID-19, we’re now watching a new disease – monkeypox – make its way around the world. SARS-CoV-2 was identified in 2019, but the first recorded human case of monkeypox was half a century earlier – so what is making the virus’ current spread so newsworthy and why is it spreading so quickly?

Though monkeypox is endemic in West and Central Africa, cases of the disease have now been detected in 27 non-endemic countries (and that number is steadily growing). The virus is usually spread through contact with an infected animal, but the latest outbreak is spreading via human-to-human transmission. Fortunately, monkeypox virus tends to mutate more slowly than SARS-CoV-2, making it less likely to evolve and find new ways to spread.

Testing troubles

Widespread testing has not yet been introduced in countries such as the US and UK – but, if the need arises, do governments and healthcare organizations have the structural capabilities and resources to implement such plans? To diagnose monkeypox, samples from the blisters and scabs are taken and sent to the lab for polymerase chain reaction (PCR) testing. Samples must be refrigerated (2–8°C) or frozen (-20°C or lower) within an hour of collection (1). Furthermore, monkeypox is a WHO Risk Group 3 pathogen, which requires laboratorians to handle samples with the utmost care and comes with specific guidance on who should perform testing.

“The smallpox vaccine is thought likely to prove at least 80 percent effective against monkeypox as they are closely related viruses. Here in the UK, we stopped regularly vaccinating against smallpox way back in 1971. Anyone under the age of 50 is unlikely to have been immunized,”  said Quinton Fivelman, Chief Scientific Officer at London Medical Laboratory, UK (2). “America’s [CDC] says that, where possible, only vaccinated people (i.e., smallpox vaccination within the past 10 years) should perform laboratory work that involves handling specimens that may contain monkeypox virus. It says non-immunized people must use increased personal protection equipment and improved practices should be followed to further reduce the risk of exposure.”

Risk of misinformation

Since the first reported case of monkeypox outside West and Central Africa, Western media outlets have been reporting daily on its spread. But, if we hadn’t spent the last two and a half years living in a pandemic, would the monkeypox outbreak have been covered so closely? Of course, COVID-19 shone a spotlight on the infectious disease landscape that won’t go away anytime soon, but we must not forget the lessons learned when reporting emerging outbreaks – whether caused by novel pathogens or known offenders.

Public-facing science communication took a hit in the early stages of the pandemic (and persisted throughout), with misinformation polluting every corner of the Internet. Monkeypox and COVID-19 are not the same, but we must apply what we’ve learned to prevent rampant misinformation – and to avoid inciting abuse and stigma against specific groups of people.

For instance, so far, monkeypox has appeared to disproportionately affect men who have sex with men. Although susceptible populations must be educated to recognize the symptoms and prevent transmission, healthcare organizations and the media must be careful and balanced to avoid feeding prejudices against gay and bisexual men. The virus can affect anyone, regardless of sexuality – and scientists and doctors must ensure that they relay reliable, scientifically correct information and limit the spread of misinformation.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. Centers for Disease Control and Protection (2022). Available at: https://bit.ly/3msQyGd.
  2. David Jinks Milt (2022). Available at: https://bit.ly/3MAyJj1.
About the Author
Liv Gaskill

During my undergraduate degree in psychology and Master’s in neuroimaging for clinical and cognitive neuroscience, I realized the tasks my classmates found tedious – writing essays, editing, proofreading – were the ones that gave me the greatest satisfaction. I quickly gathered that rambling on about science in the bar wasn’t exactly riveting for my non-scientist friends, so my thoughts turned to a career in science writing. At Texere, I get to craft science into stories, interact with international experts, and engage with readers who love science just as much as I do.

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register